T-Plex

T-Plex was a biotechnology company focused on the development of next-generation T-cell therapies through a proprietary multiplexed T-cell engineering platform. Spun out from the University of Pennsylvania, the company was founded by a team of pioneers in the field of CAR-T therapy, including Dr. Carl June and Dr. Bruce Levine. The T-Plex platform was designed to enable the simultaneous editing of multiple genes in T-cells, allowing for the creation of more potent and resilient cell therapies capable of overcoming the immunosuppressive environments of solid tumors. In 2018, the company was acquired by Tmunity Therapeutics to integrate its advanced multiplexing capabilities into Tmunity's broader portfolio of T-cell medicines, which was subsequently acquired by Kite, a Gilead Company.